Browse the corpus

The cosyntropin stimulation test is a dynamic endocrine test used to evaluate adrenal cortical function and assess the integrity of the hypothalamic–pituitary–adrenal (HPA) axis. Cosyntropin is a synthetic analog of adrenocorticotropic hormone (ACTH) that stimulates the adrenal cortex to produce cortisol.[1][2] By measuring serum cortisol levels before and after cosyntropin administration, clinicians can determine whether the adrenal glands respond appropriately to ACTH stimulation. This test is most commonly used to evaluate suspected adrenal insufficiency, including primary adrenal insufficiency (Addison disease) and certain cases of secondary or tertiary adrenal insufficiency.[2] The test is critical in differentiating causes of cortisol deficiency, supporting timely diagnosis, and guiding appropriate glucocorticoid replacement therapy to prevent adrenal crisis.[1]

The cosyntropin stimulation test evaluates adrenal cortical function by directly measuring the adrenal gland’s ability to produce cortisol in response to supraphysiologic ACTH stimulation. This assessment provides valuable insight into the integrity of the HPA axis, although important limitations exist when distinguishing between primary and secondary causes of adrenal insufficiency. The test may be performed at any time of day, as results are not significantly influenced by diurnal variation.[2][6] In cases of glucocorticoid-induced adrenal insufficiency, the test helps assess whether chronic exogenous glucocorticoid exposure has led to sufficient adrenocortical atrophy to impair cortisol responsiveness. However, diagnostic reliability may be reduced in patients with shorter therapy durations.[4] Importantly, the cosyntropin stimulation test should never delay empiric glucocorticoid administration in patients with suspected adrenal crisis. Definitive diagnostic testing can be completed after the patient has been clinically stabilized.[6] Mechanism of Action Cosyntropin is a synthetic analog comprising the first 24 amino acids of the native 39–amino acid ACTH molecule.[2] When administered at the standard 250 μg dose, cosyntropin produces supraphysiologic stimulation of the adrenal cortex by binding to melanocortin-2 receptors on adrenocortical cells, thereby triggering cortisol synthesis and secretion.[7] In healthy individuals, doses as low as 5 to 10 μg are sufficient to produce near-maximal adrenal stimulation.[7] Evaluation of Adrenal Cortical Function The cosyntropin stimulation test directly measures the functional reserve of the adrenal cortex. Serum cortisol samples are obtained at baseline and at 30 and 60 minutes following cosyntropin administration.[1] A peak cortisol level below 500 nmol/L (18 μg/dL) at either 30 and 60 minutes is consistent with adrenocortical insufficiency, although specific diagnostic thresholds vary by assay. Liquid chromatography–tandem mass spectrometry (LC-MS/MS) assays use lower cutoffs of approximately 412 nmol/L at 30 minutes and 485 nmol/L at 60 minutes.[4][8]

The cosyntropin stimulation test directly measures the functional reserve of the adrenal cortex. Serum cortisol samples are obtained at baseline and at 30 and 60 minutes following cosyntropin administration.[1] A peak cortisol level below 500 nmol/L (18 μg/dL) at either 30 and 60 minutes is consistent with adrenocortical insufficiency, although specific diagnostic thresholds vary by assay. Liquid chromatography–tandem mass spectrometry (LC-MS/MS) assays use lower cutoffs of approximately 412 nmol/L at 30 minutes and 485 nmol/L at 60 minutes.[4][8] In primary adrenal insufficiency, destruction or dysfunction of the adrenal cortex prevents an appropriate cortisol response to ACTH stimulation, regardless of the dose administered.[2] Under these conditions, the cosyntropin stimulation test functions as the diagnostic gold standard because endogenous ACTH secretion is already maximally elevated and exogenous cosyntropin fails to elicit a significant increase in cortisol secretion.[7] Assessment of Hypothalamic–Pituitary–Adrenal Axis Integrity The cosyntropin stimulation test provides an indirect and limited assessment of the entire HPA axis. In secondary adrenal insufficiency (pituitary ACTH deficiency) and tertiary adrenal insufficiency (hypothalamic CRH deficiency), chronic ACTH deficiency leads to progressive adrenocortical atrophy.[7] When atrophy is advanced, the adrenal glands may fail to respond adequately even to supraphysiologic doses of cosyntropin, leading to an abnormal test result.[1] Important limitations affect the detection of secondary and tertiary adrenal insufficiency. A meta-analysis demonstrated a sensitivity of 64% and a specificity of 93% for secondary adrenal insufficiency.[1] Patients with mild or recent-onset ACTH deficiency may have normal test results because a supraphysiologic cosyntropin dose can partially stimulate atrophied adrenal glands that would not respond appropriately to physiologic ACTH levels.[1][7] In such cases, alternative dynamic testing, such as the insulin tolerance test, overnight metyrapone test, or glucagon stimulation test, may be required when clinical suspicion remains high despite a normal cosyntropin test.[1]

Optimal management of patients undergoing cosyntropin stimulation testing, as well as those diagnosed with adrenal insufficiency, depends on coordinated interprofessional collaboration, patient education, and systematic strategies to prevent adrenal crisis. Healthcare teams must balance diagnostic accuracy while prioritizing patient safety and supporting patients to manage their conditions effectively. Nurses play a critical role in monitoring for hypersensitivity reactions during and after cosyntropin administration, as anaphylaxis has been reported. Nursing responsibilities also include ensuring the precise timing of blood draws at baseline and at 30 and 60 minutes, as timing accuracy directly influences diagnostic reliability. Pharmacists should review medication histories to identify agents that may interfere with test interpretation. Glucocorticoids and spironolactone should be withheld on the day of testing, and estrogen-containing medications should be discontinued 4 to 6 weeks in advance. In suspected glucocorticoid-induced adrenal insufficiency, glucocorticoid therapy should generally be withheld for at least 24 hours before dynamic testing, when clinically appropriate. Early-morning cortisol measurement offers a practical initial approach to evaluating adrenal insufficiency in the appropriate clinical setting. Clinicians must nonetheless balance diagnostic evaluation with the imperative to avoid delaying life-saving treatment when an adrenal crisis is suspected.